Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial - Takeaways - MDSpire

Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial

  • By

  • Mengyao Liu

  • Zengjun Liu

  • Jing Xu

  • Xin Xu

  • Qibing Wu

  • Dongyuan Zhu

  • June 8, 2026

  • 0 min

Share

  • 1

    The study evaluated tislelizumab combined with gemcitabine for locally advanced or metastatic urothelial carcinoma patients unfit for cisplatin.

  • 2

    Thirty patients were enrolled, showing a median progression-free survival of 13.9 months and a median overall survival of 23.3 months.

  • 3

    The confirmed objective response rate was 46.7%, and the disease control rate was 76.7%, indicating promising preliminary efficacy.

  • 4

    Common treatment-related adverse events included hematological toxicities, with leukopenia and neutropenia affecting 43.3% and 40.0% of patients, respectively.

  • 5

    The study suggests that tislelizumab and gemcitabine may be a viable first-line treatment option for cisplatin-intolerant urothelial carcinoma patients.

Original Source(s)

Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial

  • by Mengyao Liu, Zengjun Liu, Jing Xu, Xin Xu, Qibing Wu, Dongyuan Zhu

  • June 8, 2026

Related Content

Multiple primary head and neck cancers: a scenario-based framework for diagnosis and modern multidisciplinary management

Tagraxofusp in adult blastic plasmacytoid dendritic cell neoplasm: clinical trials and real-world outcomes: a systematic review

Association between tumor genomic mutations and the risk of PD-1 inhibitor-induced hypophysitis: a retrospective cohort study